Amicus Therapeutics Long Term Debt 2007-2021 | FOLD

Amicus Therapeutics long term debt from 2007 to 2021. Long term debt can be defined as the sum of all long term debt fields.
Amicus Therapeutics Annual Long Term Debt
(Millions of US $)
2020 $389
2019 $150
2018 $322
2017 $164
2016 $154
2015 $
2014 $11
2013 $14
2012 $0
2011 $
2010 $1
2009 $2
2008 $0
2007 $1
2006 $2
2005 $
Amicus Therapeutics Quarterly Long Term Debt
(Millions of US $)
2021-06-30 $390
2021-03-31 $390
2020-12-31 $389
2020-09-30 $389
2020-06-30 $150
2020-03-31 $150
2019-12-31 $150
2019-09-30 $149
2019-06-30 $149
2019-03-31 $205
2018-12-31 $322
2018-09-30 $319
2018-06-30 $169
2018-03-31 $167
2017-12-31 $164
2017-09-30 $162
2017-06-30 $159
2017-03-31 $157
2016-12-31 $154
2016-09-30 $22
2016-06-30 $22
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31 $9
2014-12-31 $11
2014-09-30 $12
2014-06-30 $13
2014-03-31 $14
2013-12-31 $14
2013-09-30
2013-06-30 $0
2013-03-31 $0
2012-12-31 $0
2012-09-30 $0
2012-06-30 $0
2012-03-31 $1
2011-12-31
2011-09-30 $0
2011-06-30 $0
2011-03-31 $1
2010-12-31 $1
2010-09-30 $1
2010-06-30 $2
2010-03-31 $2
2009-12-31 $2
2009-09-30 $3
2009-06-30 $2
2009-03-31 $0
2008-12-31 $0
2008-09-30 $0
2008-06-30 $1
2008-03-31 $1
2007-12-31 $1
2007-09-30 $2
2007-06-30 $2
2007-03-31
2006-09-30
2006-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.799B $0.261B
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76